Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GYN06-106

A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

  • D. Matei, J. Schilder, N. Menning, K. Koneru, G. Sutton. A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer: Hoosier Oncology Group GYN06-106. Accepted for poster presentation at the 2007 AACR (American Association for Cancer Research) -NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA

Manuscripts/Articles:

  • Daniela Matei, Jeanne Schilder, Gregory Sutton, Susan Perkins, Tim Breen, Check Quon, Carolyn Sidor. Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN06-106. Gynecologic Oncology 115 (2009) 90–96. PMID: 19577796